Peginterferon Alpha-2a

DRUG6 trials

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Virginia Commonwealth University, Novartis, Bristol-Myers Squibb, AbbVie (prior sponsor, Abbott)

Conditions

Chronic Hepatitis C InfectionChronic Hepatitis C Virus Genotype 1CirrhosisFibrosisHCVHepatitis BHepatitis CHepatitis C Genotype 1

Phase 2

Pegylated Interferon to Treat Chronic Hepatitis D

CompletedNCT00023322

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Hepatitis D

Start: 2001-08-31End: 2012-10-31Updated: 2013-07-10

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)

CompletedNCT00874770

Bristol-Myers SquibbHepatitis C Infection

Start: 2009-06-30End: 2011-01-31Updated: 2015-10-23

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

CompletedNCT01074008

AbbVie (prior sponsor, Abbott)Chronic Hepatitis C Infection, HCV, Hepatitis C +1

Start: 2010-03-31End: 2012-01-31Updated: 2015-01-08

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I

WithdrawnNCT01142700

Bristol-Myers SquibbChronic Hepatitis C Virus Genotype 1

Start: 2010-07-31End: 2010-12-31Updated: 2011-03-15

Phase 3

Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)

TerminatedNCT00412750

NovartisHepatitis B

Start: 2006-12-31End: 2009-02-28Updated: 2011-07-13

Unknown Phase

Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C

CompletedNCT00252642

Virginia Commonwealth UniversityCirrhosis, Fibrosis, Hepatitis C

Start: 2005-11-30End: 2007-09-30Updated: 2017-03-20

Related Papers

Durable virological response and functional cure of chronic hepatitis D after long‐term peginterferon therapy

Alimentary Pharmacology & Therapeutics2021-05-2822 citations

Hepatitis D Virus-Specific CD8<sup>+</sup> T Cells Have a Memory-Like Phenotype Associated With Viral Immune Escape in Patients With Chronic Hepatitis D Virus Infection.

2019-01-1844 citations

<i>In Vitro</i> and <i>In Vivo</i> Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450

Antimicrobial Agents and Chemotherapy2014-12-02116 citations

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.

2012-06-18116 citations